We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Test Improves Diagnosis of Tuberculous Meningitis in HIV Patients

By LabMedica International staff writers
Posted on 07 Nov 2013
Tuberculous meningitis (TBM) is a serious and often fatal illness that is difficult to diagnose particularly in resource-poor areas and is especially common in individuals infected with the human immunodeficiency virus (HIV).

A newly available DNA test that can be used in these resource-poor settings and is generally used to detect Mycobacterium tuberculosis (TB), the causative organism, in sputum, and to detect TB DNA in cerebrospinal fluid, has been evaluated for TBM. More...


Microbiologists at the University of KwaZulu-Natal (Durban, South Africa) performed an evaluation study in 204 South African patients with a meningeal-like illness, of whom 87% were HIV-infected. In this cohort, using a gold standard of positive culture or traditional polymerase chain reaction (PCR) to determine who truly had TBM, 59 individuals had definite TBM, 64 had probable TBM, and 81 did not have TBM. These patients were recruited from hospitals in South Africa between January 2008 and December 2011.

The newly available test was the Xpert MTB/RIF (Cepheid; Sunnyvale, CA, USA) which is an integrated automated sample-processing and real-time PCR platform developed to simultaneously detect M. tuberculosis and rifampicin resistance in a single-use-cartridge hands-free step. The sensitivity of Xpert MTB/RIF was significantly better than that of smear microscopy (62% versus 12%) and significantly better than that of clinical signs (CS) (62% versus 30%) The sensitivity of the Xpert MTB/RIF was higher when centrifuged versus uncentrifuged samples were used (82% versus 47%). The test did not perform as well in the few individuals who were not HIV-infected.

The Xpert MTB/RIF test correctly identified more positive cases than the other tests used to diagnose TB meningitis, within 24 hours of first seeing a patient. However, the test accuracy was more robust when the cerebrospinal fluid sample was centrifuged to achieve the best results. This means additional apparatus would be required, resulting in higher cost and requiring more training. The scientists concluded that this test could still be useful in settings where resources are limited.

The authors concluded that Xpert MTB/RIF might be a good rule-in test for the diagnosis of TBM in HIV-infected individuals from a tuberculosis-endemic setting, particularly when a centrifuged CSF pellet is used. Further studies are required to confirm these findings in different settings. The study was published on October 22, 2013, in the journal Public Library of Science Medicine.

Related Links:

University of KwaZulu-Natal
Cepheid



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.